These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 26890396)

  • 1. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.
    Kleb B; Estécio MR; Zhang J; Tzelepi V; Chung W; Jelinek J; Navone NM; Tahir S; Marquez VE; Issa JP; Maity S; Aparicio A
    Epigenetics; 2016 Mar; 11(3):184-93. PubMed ID: 26890396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth.
    Shiota M; Takeuchi A; Yokomizo A; Kashiwagi E; Tatsugami K; Naito S
    J Urol; 2012 Jul; 188(1):300-6. PubMed ID: 22608750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.
    Liu C; Wang C; Wang K; Liu L; Shen Q; Yan K; Sun X; Chen J; Liu J; Ren H; Liu H; Xu Z; Hu S; Xu D; Fan Y
    J Natl Cancer Inst; 2013 Nov; 105(22):1719-28. PubMed ID: 24174655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
    Fialova B; Smesny Trtkova K; Paskova L; Langova K; Kolar Z
    Oncol Rep; 2013 May; 29(5):2039-45. PubMed ID: 23503510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic modulation of AR gene expression in prostate cancer DU145 cells with the combination of sodium butyrate and 5'-Aza-2'-deoxycytidine.
    Fialova B; Luzna P; Gursky J; Langova K; Kolar Z; Trtkova KS
    Oncol Rep; 2016 Oct; 36(4):2365-74. PubMed ID: 27499010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells.
    Jarrard DF; Kinoshita H; Shi Y; Sandefur C; Hoff D; Meisner LF; Chang C; Herman JG; Isaacs WB; Nassif N
    Cancer Res; 1998 Dec; 58(23):5310-4. PubMed ID: 9850055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
    Obinata D; Takayama K; Lawrence MG; Funakoshi D; Hara M; Niranjan B; Teng L; Taylor RA; Risbridger GP; Takahashi S; Inoue S
    BMC Cancer; 2024 May; 24(1):554. PubMed ID: 38698344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.
    Wang HJ; Pochampalli M; Wang LY; Zou JX; Li PS; Hsu SC; Wang BJ; Huang SH; Yang P; Yang JC; Chu CY; Hsieh CL; Sung SY; Li CF; Tepper CG; Ann DK; Gao AC; Evans CP; Izumiya Y; Chuu CP; Wang WC; Chen HW; Kung HJ
    Oncogene; 2019 Jan; 38(1):17-32. PubMed ID: 30072740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling a lethal prostate cancer variant with small-cell carcinoma features.
    Tzelepi V; Zhang J; Lu JF; Kleb B; Wu G; Wan X; Hoang A; Efstathiou E; Sircar K; Navone NM; Troncoso P; Liang S; Logothetis CJ; Maity SN; Aparicio AM
    Clin Cancer Res; 2012 Feb; 18(3):666-77. PubMed ID: 22156612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer.
    Schayek H; Bentov I; Jacob-Hirsch J; Yeung C; Khanna C; Helman LJ; Plymate SR; Werner H
    Horm Metab Res; 2012 Jun; 44(7):511-9. PubMed ID: 22495974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
    Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2.
    Mukhopadhyay NK; Kim J; You S; Morello M; Hager MH; Huang WC; Ramachandran A; Yang J; Cinar B; Rubin MA; Adam RM; Oesterreich S; Di Vizio D; Freeman MR
    Oncogene; 2014 Jun; 33(25):3235-45. PubMed ID: 23893242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer.
    Corella AN; Cabiliza Ordonio MVA; Coleman I; Lucas JM; Kaipainen A; Nguyen HM; Sondheim D; Brown LG; True LD; Lee JK; MacPherson D; Nghiem P; Gulati R; Morrissey C; Corey E; Nelson PS
    Clin Cancer Res; 2020 Apr; 26(7):1667-1677. PubMed ID: 31806643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters.
    Ngollo M; Lebert A; Dagdemir A; Judes G; Karsli-Ceppioglu S; Daures M; Kemeny JL; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon D
    BMC Cancer; 2014 Dec; 14():994. PubMed ID: 25535400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
    Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demethylation of the miR-146a promoter by 5-Aza-2'-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer.
    Wang X; Gao H; Ren L; Gu J; Zhang Y; Zhang Y
    BMC Cancer; 2014 May; 14():308. PubMed ID: 24885368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.
    Poirier JT; Gardner EE; Connis N; Moreira AL; de Stanchina E; Hann CL; Rudin CM
    Oncogene; 2015 Nov; 34(48):5869-78. PubMed ID: 25746006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP.
    Karpf AR; Bai S; James SR; Mohler JL; Wilson EM
    Mol Cancer Res; 2009 Apr; 7(4):523-35. PubMed ID: 19372581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer.
    Cao S; Ma T; Ungerleider N; Roberts C; Kobelski M; Jin L; Concha M; Wang X; Baddoo M; Nguyen HM; Corey E; Fazli L; Ledet E; Zhang R; Silberstein JL; Zhang W; Zhang K; Sartor O; Dong X; Flemington EK; Dong Y
    Oncogene; 2019 Nov; 38(45):7060-7072. PubMed ID: 31409897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation and methylation of tumor suppressor miR-124 by androgen receptor in prostate cancer cells.
    Chu M; Chang Y; Guo Y; Wang N; Cui J; Gao WQ
    PLoS One; 2015; 10(4):e0116197. PubMed ID: 25860954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.